Molecular imaging in the development of a novel treatment paradigm for glioblastoma (GBM): an integrated multidisciplinary commentary
Authors:
- Monika A. JarzabekMJMonika A. Jarzabek
- Kieron J. SweeneyKSKieron J. Sweeney
- Rhys L. EvansRERhys L. Evans
- Andreas H. JacobsAJAndreas H. Jacobs
- Roger StuppRSRoger Stupp
- Donncha O’bRienDODonncha O’bRien
- Mitchel S. BergerMBMitchel S. Berger
- Jochen H.M. PrehnJochen H.M. Prehn
- Annette T. ByrneABAnnette T. Byrne
- 1 November 2013
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 18 (21-22) , 1052-1066
Abstract
No abstract availableKeywords
This publication has 101 references indexed in Scilit:
- Hyperpolarized 13C MR spectroscopic imaging can be used to monitor Everolimus treatment in vivo in an orthotopic rodent model of glioblastomaNeuroImage, 2012
- Glioma Stem Cell Proliferation and Tumor Growth Are Promoted by Nitric Oxide Synthase-2Cell, 2011
- Targeting the mTOR kinase domain: the second generation of mTOR inhibitorsDrug Discovery Today, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularityJournal of Magnetic Resonance Imaging, 2010
- Perfusion MRI of brain tumours: a comparative study of pseudo-continuous arterial spin labelling and dynamic susceptibility contrast imagingNeuroradiology, 2009
- Volumetry of [11C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiformeEuropean Journal of Nuclear Medicine and Molecular Imaging, 2009
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trialThe Lancet Oncology, 2006